**Table E1:** Summary of adverse events occurring during one year of treatment with mepolizumab

|  |  |
| --- | --- |
| **Adverse Events** | **Number & % AE** |
| **Bruising** | 1 (5.3%) |
| **Chalazion** | 1 (5.3%) |
| **Conjunctivitis** | 1 (5.3%) |
| **Dizziness** | 4 (21.0%) |
| **Hair loss** | 1 (5.3%) |
| **Fatigue** | 1 (5.3%) |
| **Headache** | 3 (15.8%) |
| **Itching** | 1 (5.3%) |
| **Local injection site reactions** | 1 (5.3%) |
| **Musculoskeletal pain** | 3 (15.8%) |
| **Otitis media** | 1 (5.3%) |
| **Productive cough** | 1 (5.3%) |
| **Rhinitis-Nasal congestion** | 5 (26.3%) |
| **Upper respiratory tract infection** | 5 (26.3%) |
| **Urinary tract infection** | 1 (5.3%) |